VMD

Viemed is a durable, self-funded compounder. Revenue has more than doubled from $117M (FY2021) to $270M (FY2025) without a single down year, and FY2025 grew 20.5% while net income rose 32.6% to $14.9M and diluted EPS climbed 32.1% to $0.37. That is the profile of a business gaining operating leverage: operating income (+28.2%) and gross profit (+16.7%) are both scaling, and the company's asset-light, personnel-first model — 'focusing overhead costs on personnel that service the patient rather than physical location costs' — is what lets it enter all 50 states and grow without heavy fixed-cost drag. Gross margin of 57.5% and a 10.6% ROE on a modestly levered book (liabilities/equity just 0.39x) point to a genuinely healthy franchise, not growth bought with debt.

The balance sheet is the reassuring anchor. Stockholders' equity is $142M against only $55.6M of total liabilities and $12.4M of total debt, with $103M of retained earnings — this company has funded its expansion out of operating cash flow ($51.9M, +32.8%), exactly as the MD&A states ('Our primary sources of capital to date have been from operating cash flows'), while still buying back $13.2M of stock and shrinking the share count 2.3%. Management retains $60M of undrawn revolver/term capacity plus a $30M accordion, so liquidity is ample despite the thin $13.5M cash balance.